Visual follow-up in peroxisomal-disorder patients treated with docosahexaenoic acid ethyl ester

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 2277-2285

  Teresa Noguer, M ^a   Martinez, Manuela ^b  

^a Laboratory Department   (Spain)

^b Research Laboratory   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; 4,7,10,13,16,19 DOCOSAHEXAENOIC ACID ETHYL ESTER; 4,7,10,13,16,19-DOCOSAHEXAENOIC ACID ETHYL ESTER;

ARTICLE; BRAIN FUNCTION; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; D FUNCTIONAL PROTEIN DEFICIENCY; DISORDERS OF PEROXISOMAL FUNCTIONS; DOCOSAHEXAENOIC ACID DEFICIENCY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; INFANT; MALE; NYSTAGMUS; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSORY SYSTEM ELECTROPHYSIOLOGY; VISION; VISUAL ACUITY; ZELLWEGER SYNDROME; BLOOD; FOLLOW UP; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA;

CHILD; CHILD, PRESCHOOL; DOCOSAHEXAENOIC ACIDS; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PEROXISOMAL DISORDERS; RETINA; VISUAL ACUITY;

EID: 77951248337     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4020     Document Type: Article

References (45)

1. Bowen P, Lee CSM, Zellweger H, Lindenberg R. A familial syndrome of multiple congenital defects. Bull Johns Hopkins Hosp. 1964;114:402-414.
2. Goldfisher S, Moore CL, Johnson AB, et al. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science. 1973;182:62-64.
3. Subramani S. Components involved in peroxisome import, biogenesis, proliferation, turnover, and movement. Physiol Rev. 1998;78: 171-188.
4. Santos MJ, Imanaka T, Shio H, Small GM, Lazarow PB. Peroxisomal membrane ghosts in Zellweger syndrome: aberrant organelle assembly. Science. 1988;239:1536-1538.
5. Lazarow PB, Moser HW. Disorders of peroxisome biogenesis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill; 1995:2287-2324.
6. Moser AB, Singh I, Brown FR III, et al. The cerebro-hepato-rena (Zellweger) syndrome: increased levels and impaired degradation of very long chain fatty acids and their use in prenatal diagnosis. N Engl J Med. 1984;310:1141-1146.
7. Hajra AK, Bishop JE. Glycerolipid biosynthesis in peroxisomes via the acyl dihydroxyacetonephosphate pathway. Ann N Y Acad Sci. 1982;386:170-182.
8. Poulos A, Sharp P, Fellenberg AJ, et al. Cerebro-hepato-renal (Zellweger) syndrome, adrenoleukodystrophy and Refsum's disease: plasma changes and skin fibroblast phytanic acid oxidase. Hum Genet. 1985;70:172-177.
9. Hanson RF, Szczepanik-van Leeuwen P, Williams GC, et al. Defects of bile acids synthesis in Zellweger's syndrome. Science. 1979;203: 1107-1108.
10. Martinez M. Altered unsaturated fatty acid patterns in Zellweger syndrome. Neurochem Int. 1988;13(suppl 1):148.
11. Martinez M. Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids. 1989;24:261-265.
12. Martinez M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of _4 desaturation? Neurology. 1990;40: 1292-1298.
13. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res. 1992;583:171-182.
14. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992;120:S129-S138.
15. Fliesler SJ, Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res. 1983;22:79-131.
16. Martinez M, Gil-Gibernau JJ, Ballabriga A. Lipids of the developing human retina: I, total fatty acids, plasmalogens, and fatty acid composition of ethanolamine and choline phosphoglycerides. J Neurosci Res. 1988;20:484-490.
17. Anderson RE, Benolken RM, Dudley PA, Landis DJ, Wheeler TG. Proceedings: polyunsaturated fatty acids of photoreceptor membranes. Exp Eye Res. 1974;18:205-213.
18. Soubias O, Teague WE, Gawrisch K. Evidence for specificity in lipid-rhodopsin interactions. J Biol Chem. 2006;281:33233-33241.
19. Grossfield A. Modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc Natl Acad Sci U S A. 2006;103:4888-4893.
20. Chen Y, Houghton LA, Brenna JT, Noy N. Docosahexaenoic acid modulates the interactions of the interphotoreceptor retinoidbinding protein with 11-cis-retinal. J Biol Chem. 1996;271:20507-20515.
21. Niu SL, Mitchell DC, Lim SY, et al. Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. J Biol Chem. 2004;279:31098-31104.
22. Neuringer M, Connor WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci U S A. 1986;83:4021-4025.
23. Weisinger HS, Vingrys AJ, Sinclair AJ. The effect of docosahexaenoic acid on the electroretinogram of the guinea pig. Lipids. 1996;31:65-70.
24. Heinemann KM, Waldron MK, Bigley KE, Lees GE, Bauer JE. Longchain (n-3) polyunsaturated fatty acids are more efficient than alpha-linolenic acid in improving electroretinogram responses of puppies exposed during gestation, lactation, and weaning. J Nutr. 2005;135:1960-1966.
25. Faldella G, Govoni M, Alessandroni R, et al. Visual evoked potentials and dietary long chain polyunsaturated fatty acids in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1996;75:F108-F112.
26. Hoffman DR, Birch EE, Birch DG, et al. Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. J Pediatr Gastroenterol Nutr. 2000;31:540-553.
27. Malcolm CA, Hamilton R, McCulloch DL, Montgomery C, Weaver LT. Scotopic electroretinogram in term infants born of mothers supplemented with docosahexaenoic acid during pregnancy. Invest Ophthalmol Vis Sci. 2003;44:3685-3691.
28. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. Biol Chem. 1991;266:19995-20000.
29. Converse CA, Hammer HM, Packard CJ, Shepherd J. Plasma lipid abnormalities in retinitis pigmentosa and related conditions. Trans Ophthalmol Soc UK. 1983;103:508-512.
30. Schaefer EJ, Robins SJ, Patton GM, et al. Red blood cell membrane phosphatidylethanolamine fatty acid content in various forms of retinitis pigmentosa. J Lipid Res. 1995;36:1427-1433.
31. Hoffman DR, Birch DG. Docosahexaenoic acid in red blood cells of patients with X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1995;36:1009-1018.
32. Lyons CL, Castano G, McCormick AQ, Applegarth D. Leopard spot retinal pigmentation in infancy indicating a peroxisomal disorder. Br J Ophthalmol. 2004;88:191-192.
33. Glasgow BJ, Brown HH, Hannah JB, Foss RY. Ocular pathologic findings in neonatal adrenoleukodystrophy. Ophthalmology. 1987;8:1054-1060.
34. Cohen SM, Brown FR 3rd, Martyn L, et al. Ocular histopathologic and biochemical studies of the cerebrohepatorenal syndrome (Zellweger's syndrome) and its relationship to neonatal adrenoleukodystrophy. Am J Ophthalmol. 1983;96:488-501.
35. Kori AA, Robin NH, Jacobs JB, et al. Pendular nystagmus in patients with peroxisomal assembly disorder. Arch Neurol. 1998;55:554-558.
36. Chen H, Anderson RE. Differential incorporation of docosahexaenoic and arachidonic acids in frog retinal pigment epithelium. J Lipid Res. 1993;34:1943-1955.
37. Martinez M. Treatment with docosahexaenoic acid favorably modifies the fatty acid composition of erythrocytes in peroxisomal patients. In: Coates PM, Tanaka K, eds. New Developments in Fatty Acid Oxidation. New York: Wiley-Liss; 1992; 389-397.
38. Martinez M, Pineda M, Vidal R, Martin B. Docosahexaenoic acid: a new therapeutic approach to peroxisomal-disorder patients-experience with two cases, Neurology. 1993;43:1389-1397.
39. Martinez M. Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. J Inher Metab Dis. 1995;18(suppl 1):61-75.
40. Martinez M. Docosahexaenoic acid therapy in DHA-deficient patients with disorders of peroxisomal biogenesis. Lipids. 1996;31: S145-S152.
41. Martinez M, Vazquez E. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology. 1998;51:26-32.
42. Martinez M, Vazquez E, García Silva MT, et al. Therapeutical effects of docosahexaenoic acid in patients with generalized peroxisomal disorders. Am J Clin Nutr. 2000;71:376S-385S.
43. Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neursci. 2001;16:225-232.
44. Maksoud SAA, El-Bassyouni HT, Afifi HH, Khalifa AG. The role of DHA in amelioration of symptoms of peroxisome biogenesis disorders. Res J Med Med Sci. 2007;2:5-13.
45. Pigassou R. Entente cordiale in the early treatment of squint. Br J Ophthalmol. 1977;61:16-22.